UK markets open in 2 hours 23 minutes

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.5200-0.0200 (-1.30%)
At close: 04:00PM EDT
1.5300 +0.01 (+0.66%)
After hours: 07:43PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 117.16M
Enterprise value 211.24M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.50
Price/book (mrq)74.89
Enterprise value/revenue 2.80
Enterprise value/EBITDA -1.20

Trading information

Stock price history

Beta (5Y monthly) 0.25
52-week change 3-70.94%
S&P500 52-week change 3-10.17%
52-week high 38.8700
52-week low 31.2600
50-day moving average 35.6498
200-day moving average 36.5429

Share statistics

Avg vol (3-month) 33.55M
Avg vol (10-day) 310.93M
Shares outstanding 576.57M
Implied shares outstanding 6N/A
Float 866.34M
% held by insiders 10.96%
% held by institutions 199.39%
Shares short (27 Feb 2023) 417.25M
Short ratio (27 Feb 2023) 49.4
Short % of float (27 Feb 2023) 427.02%
Short % of shares outstanding (27 Feb 2023) 422.53%
Shares short (prior month 30 Jan 2023) 418.85M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-237.83%

Management effectiveness

Return on assets (ttm)-35.64%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)75.47M
Revenue per share (ttm)1.14
Quarterly revenue growth (yoy)22.20%
Gross profit (ttm)-70.42M
EBITDA -179M
Net income avi to common (ttm)-233.66M
Diluted EPS (ttm)-3.5400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)166.86M
Total cash per share (mrq)2.18
Total debt (mrq)504.55M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.67
Book value per share (mrq)-4.34

Cash flow statement

Operating cash flow (ttm)-174.83M
Levered free cash flow (ttm)-135.56M